Physician profile
Steven N Ha
NPI 1477607737
$4,183.37
in general payments reported to CMS, 2019-2025
18 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $356 · 2021: $660 · 2022: $528 · 2023: $976 · 2024: $812 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,010.99 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $673.58 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $458.13 | 2020-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $381.15 | 2020-2025 | |
| Lilly USA, LLC | $319.23 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Exact Sciences Corporation | $288.79 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.16 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $169.96 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Arbor Pharmaceuticals, INC. | $137.16 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $92.60 | 2021 | |
| Astellas Pharma US INC | $90.59 | 2024-2025 | Veozah |
| Abbott Laboratories | $74.74 | 2022-2023 | Freestyle Libre 2 |
| Vbi Vaccine (Delaware) INC. | $74.72 | 2022-2023 | Prehevbrio |
| Amarin Pharma, INC. | $44.61 | 2019 | |
| Azurity Pharmaceuticals, INC. | $36.61 | 2023 | Edarbi, Edarbyclor |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.61 | 2020 | |
| Tempus Ai, INC | $27.20 | 2025 | Xt Cdx |
| Phadia US INC. | $22.54 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.